001     256452
005     20240826165950.0
024 7 _ |a 10.1186/s13195-023-01187-9
|2 doi
024 7 _ |a pmid:36855049
|2 pmid
024 7 _ |a pmc:PMC9972621
|2 pmc
024 7 _ |a altmetric:143165523
|2 altmetric
037 _ _ |a DZNE-2023-00314
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Yildirim, Zerrin
|0 P:(DE-2719)9000823
|b 0
|u dzne
245 _ _ |a Brain reserve contributes to distinguishing preclinical Alzheimer's stages 1 and 2.
260 _ _ |a London
|c 2023
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1711028422_32501
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY
520 _ _ |a In preclinical Alzheimer's disease, it is unclear why some individuals with amyloid pathologic change are asymptomatic (stage 1), whereas others experience subjective cognitive decline (SCD, stage 2). Here, we examined the association of stage 1 vs. stage 2 with structural brain reserve in memory-related brain regions.We tested whether the volumes of hippocampal subfields and parahippocampal regions were larger in individuals at stage 1 compared to asymptomatic amyloid-negative older adults (healthy controls, HCs). We also tested whether individuals with stage 2 would show the opposite pattern, namely smaller brain volumes than in amyloid-negative individuals with SCD. Participants with cerebrospinal fluid (CSF) biomarker data and bilateral volumetric MRI data from the observational, multi-centric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study were included. The sample comprised 95 amyloid-negative and 26 amyloid-positive asymptomatic participants as well as 104 amyloid-negative and 47 amyloid-positive individuals with SCD. Volumes were based on high-resolution T2-weighted images and automatic segmentation with manual correction according to a recently established high-resolution segmentation protocol.In asymptomatic individuals, brain volumes of hippocampal subfields and of the parahippocampal cortex were numerically larger in stage 1 compared to HCs, whereas the opposite was the case in individuals with SCD. MANOVAs with volumes as dependent data and age, sex, years of education, and DELCODE site as covariates showed a significant interaction between diagnosis (asymptomatic versus SCD) and amyloid status (Aß42/40 negative versus positive) for hippocampal subfields. Post hoc paired comparisons taking into account the same covariates showed that dentate gyrus and CA1 volumes in SCD were significantly smaller in amyloid-positive than negative individuals. In contrast, CA1 volumes were significantly (p = 0.014) larger in stage 1 compared with HCs.These data indicate that HCs and stages 1 and 2 do not correspond to linear brain volume reduction. Instead, stage 1 is associated with larger than expected volumes of hippocampal subfields in the face of amyloid pathology. This indicates a brain reserve mechanism in stage 1 that enables individuals with amyloid pathologic change to be cognitively normal and asymptomatic without subjective cognitive decline.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease (AD)
|2 Other
650 _ 7 |a Amyloid pathologic change
|2 Other
650 _ 7 |a Aß42/40
|2 Other
650 _ 7 |a Brain reserve
|2 Other
650 _ 7 |a Cerebrospinal fluid (CSF)
|2 Other
650 _ 7 |a Hippocampus
|2 Other
650 _ 7 |a Magnetic resonance imaging (MRI)
|2 Other
650 _ 7 |a Medial temporal lobe
|2 Other
650 _ 7 |a Memory
|2 Other
650 _ 7 |a Subjective cognitive decline (SCD)
|2 Other
650 _ 7 |a Amyloidogenic Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognitive Reserve
|2 MeSH
650 _ 2 |a Amyloidogenic Proteins
|2 MeSH
650 _ 2 |a Cerebral Cortex
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
700 1 _ |a Delen, Firuze
|b 1
700 1 _ |a Berron, David
|0 P:(DE-2719)2812972
|b 2
|u dzne
700 1 _ |a Baumeister, Hannah
|0 P:(DE-2719)9001499
|b 3
|u dzne
700 1 _ |a Ziegler, Gabriel
|0 P:(DE-2719)2814076
|b 4
|u dzne
700 1 _ |a Schütze, Hartmut
|0 P:(DE-2719)9001467
|b 5
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 6
|u dzne
700 1 _ |a Dobisch, Laura
|0 P:(DE-2719)2811611
|b 7
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 8
|u dzne
700 1 _ |a Freiesleben, Silka Dawn
|0 P:(DE-2719)2812392
|b 9
|u dzne
700 1 _ |a Schneider, Luisa-Sophie
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 11
|u dzne
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-2719)2812446
|b 12
|u dzne
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 13
|u dzne
700 1 _ |a Fliessbach, Klaus
|0 P:(DE-2719)2811326
|b 14
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 15
|u dzne
700 1 _ |a Schott, Björn-Hendrik
|0 P:(DE-2719)2814326
|b 16
|u dzne
700 1 _ |a Meiberth, Dix
|0 P:(DE-2719)9000940
|b 17
|u dzne
700 1 _ |a Buerger, Katharina
|0 P:(DE-2719)2811351
|b 18
|u dzne
700 1 _ |a Janowitz, Daniel
|0 P:(DE-2719)9002557
|b 19
|u dzne
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 20
|u dzne
700 1 _ |a Rauchmann, Boris Stephan
|0 P:(DE-2719)9001808
|b 21
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 22
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 23
|u dzne
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 24
|u dzne
700 1 _ |a Munk, Matthias H
|0 P:(DE-2719)9001516
|b 25
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 26
|u dzne
700 1 _ |a Roy, Nina
|0 P:(DE-2719)2812341
|b 27
|u dzne
700 1 _ |a Heneka, Michael
|0 P:(DE-2719)2000008
|b 28
|u dzne
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 29
|u dzne
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 30
|u dzne
700 1 _ |a Roeske, Sandra
|0 P:(DE-2719)2810395
|b 31
|u dzne
700 1 _ |a Ramirez, Alfredo
|0 P:(DE-2719)2812825
|b 32
|u dzne
700 1 _ |a Ewers, Michael
|0 P:(DE-2719)9000543
|b 33
|u dzne
700 1 _ |a Dechent, Peter
|b 34
700 1 _ |a Hetzer, Stefan
|b 35
700 1 _ |a Scheffler, Klaus
|b 36
700 1 _ |a Kleineidam, Luca
|0 P:(DE-2719)2812139
|b 37
|u dzne
700 1 _ |a Wolfsgruber, Steffen
|0 P:(DE-2719)2810544
|b 38
|u dzne
700 1 _ |a Yakupov, Renat
|0 P:(DE-2719)2812398
|b 39
|u dzne
700 1 _ |a Schmid, Matthias
|0 P:(DE-2719)2811245
|b 40
|u dzne
700 1 _ |a Berger, Moritz
|b 41
700 1 _ |a Gurvit, Hakan
|b 42
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 43
|u dzne
700 1 _ |a Duzel, Emrah
|0 P:(DE-2719)2000005
|b 44
|e Last author
|u dzne
773 _ _ |a 10.1186/s13195-023-01187-9
|g Vol. 15, no. 1, p. 43
|0 PERI:(DE-600)2506521-X
|n 1
|p 43
|t Alzheimer's research & therapy
|v 15
|y 2023
|x 1758-9193
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/256452/files/DZNE-2023-00314.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/256452/files/DZNE-2023-00314.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:256452
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)9000823
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)2812972
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001499
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2814076
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001467
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811614
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811611
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)2812392
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2812446
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2811326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2814326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)9000940
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2811351
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 19
|6 P:(DE-2719)9002557
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2812234
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 21
|6 P:(DE-2719)9001808
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)9001516
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2812341
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2000008
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2810395
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 32
|6 P:(DE-2719)2812825
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 33
|6 P:(DE-2719)9000543
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 37
|6 P:(DE-2719)2812139
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 38
|6 P:(DE-2719)2810544
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 39
|6 P:(DE-2719)2812398
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 40
|6 P:(DE-2719)2811245
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 43
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 44
|6 P:(DE-2719)2000005
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 2
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-19
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:09:21Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:09:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-19
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-08
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-19
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-08
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2023-04-12T15:09:21Z
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 0
920 1 _ |0 I:(DE-2719)5000070
|k AG Berron
|l Clinical Cognitive Neuroscience
|x 1
920 1 _ |0 I:(DE-2719)1340013
|k KAP
|l Cooperation Unit for Applied Prevention Research (KAP)
|x 2
920 1 _ |0 I:(DE-2719)1810002
|k AG Dirnagl
|l Vascular Pathology
|x 3
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 4
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 5
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 6
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn
|l Patient Studies Bonn
|x 7
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 8
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 9
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 10
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 11
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 12
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 13
920 1 _ |0 I:(DE-2719)1011401
|k Clinical Research Platform (CRP)
|l Clinical Research Platform (CRP)
|x 14
920 1 _ |0 I:(DE-2719)1011301
|k Biomarker
|l Interventional Trials and Biomarkers in Neurodegenerative Diseases
|x 15
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 16
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 17
920 1 _ |0 I:(DE-2719)1013028
|k AG Schmid Bonn
|l Mathematics, statistics and informatics methods for support of population studies and clinical research
|x 18
920 1 _ |0 I:(DE-2719)5000034
|k Delcode
|l Delcode
|x 19
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)5000070
980 _ _ |a I:(DE-2719)1340013
980 _ _ |a I:(DE-2719)1810002
980 _ _ |a I:(DE-2719)5000007
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1011401
980 _ _ |a I:(DE-2719)1011301
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1110008
980 _ _ |a I:(DE-2719)1013028
980 _ _ |a I:(DE-2719)5000034
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21